NCT00186589View on ClinicalTrials.gov

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Lymphoma, Non-HodgkinBlood and Marrow Transplant (BMT)
Interventions
DRUG

90Y Ibritumomab tiuxetan

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

Stanford University

OTHER